Vaccines for Respiratory Syncytial Virus

Message from the Guest Editors

Dear Colleagues,

Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children, affecting nearly all children by the age of two years, as well as the elderly. Treatment is supportive as there is no licensed vaccine available. Improved understanding of the immunology and pathogenesis of RSV infection has led to the development of novel candidate vaccines. This Special Issue of *Vaccines* is directed toward reviewing basic and translational vaccines and disease intervention strategies for respiratory syncytial virus (RSV). This issue includes articles investigating the mechanisms of immunity and disease pathogenesis associated with RSV infection and RSV vaccines. A goal is to provide the reader with a better understanding of the conceptual and functional differences between innate and adaptive immune responses so as to provide the foundation for novel vaccines and antiviral approaches. This issue will also investigate the host and viral regulatory pathways involving regulation of immune responses RSV.

Prof. Dr. Ralph A. Tripp
Dr. Ultan F. Power
*Guest Editors*
**Editor-in-Chief**  

Prof. Dr. Ralph A. Tripp  
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia; Athens, GA 30602-7387, USA

**Message from the Editor-in-Chief**

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

**Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.  

**High visibility:** Indexed in the Science Citation Index Expanded (SCIE) and BIOSIS Previews in Web of Science and in Scopus. Citations available in PubMed, full-text archived in PubMed Central.  

**CiteScore** (2018 Scopus data): **5.43**, which equals rank 12/272 (Q1) in the category 'Infectious Diseases', rank 31/198 (Q1) in 'Immunology' and rank 15/300 (Q1) in 'Pharmacology', among others.

**Contact Us**

*Vaccines*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com  
mdpi.com/journal/vaccines  
vaccines@mdpi.com